Equity Overview
Price & Market Data
Price: $1.63
Daily Change: -$0.06 / 3.68%
Range: $1.55 - $1.73
Market Cap: $18,103,680
Volume: 169,903
Performance Metrics
1 Week: -9.60%
1 Month: 42.86%
3 Months: 29.55%
6 Months: -59.80%
1 Year: -58.55%
YTD: -48.55%
Company Details
Employees: 5
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia AND myelodysplastic syndromes; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.